title: Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial.
abstract: Sulphasalazine was administered to 18 patients with juvenile rheumatoid arthritis (JRA). The mean duration of therapy was 7.8 +/- 2.6 months. There was significant improvement in all clinical variables and erythrocyte sedimentation rate. Five children developed minor and transient side effects. Medication was discontinued in 3 patients: one because of leukopenia, 2 for lack of effect. These results suggest that sulphasalazine is an effective and relatively safe drug which may prove to be a useful second line agent in the management of JRA.
authors.forename: H
authors.initials: H
authors.lastname: Ozdogan
authors.forename: M
authors.initials: M
authors.lastname: Turunç
authors.forename: B
authors.initials: B
authors.lastname: Deringöl
authors.forename: S
authors.initials: S
authors.lastname: Yurdakul
authors.forename: H
authors.initials: H
authors.lastname: Yazici
mesh_terms: D000293:Adolescent; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D012460:Sulfasalazine; D011239:Prednisolone